• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶型纤溶酶原激活物受体的血浆浓度是同种异体肾移植功能的一个标志物。

Plasma concentration of urokinase plasminogen activator receptor is a marker of kidney allograft function.

作者信息

Staniszewska Marzena, Dziedziejko Violetta, Kwiatkowska Ewa, Tkacz Marta, Puchałowicz Kamila, Safranow Krzysztof, Domanski Leszek, Pawlik Andrzej

机构信息

Department of Physiology, Pomeranian Medical University, Powstancow Wlkp. 72, 70-111, Szczecin, Poland.

Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Powstancow Wlkp. 72, 70-111, Szczecin, Poland.

出版信息

Ir J Med Sci. 2018 Nov;187(4):1083-1087. doi: 10.1007/s11845-018-1767-4. Epub 2018 Mar 1.

DOI:10.1007/s11845-018-1767-4
PMID:29497975
Abstract

BACKGROUND

Urokinase-type plasminogen activator receptor (uPAR) is found in a variety of cell types including monocytes, lymphocytes, macrophages, and endothelial cells and plays an important role in fibrinolysis and in the activation and chemotaxis of neutrophils and lymphocytes. In this study, we examined the correlation between uPAR plasma concentration and kidney allograft function.

AIMS

This study enrolled 78 Caucasian deceased-donor renal transplant recipients.

METHODS

Plasma concentrations of uPAR were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits.

RESULTS

We observed elevated with borderline significance (p = 0.095) uPAR plasma concentrations in patients with tubular atrophy. Plasma concentrations of uPAR showed strong statistically significant positive correlations with serum creatinine or urea and strong negative correlation with estimated glomerular filtration rate (eGFR). There was also a borderline positive correlation between uPAR plasma concentration and protein concentration in urine as well as the duration of hemodialysis.

CONCLUSIONS

The results of our study indicate that uPAR plasma concentrations in kidney allograft recipients are significantly negatively correlated with graft function and may be elevated in patients with tubular atrophy.

摘要

背景

尿激酶型纤溶酶原激活物受体(uPAR)存在于多种细胞类型中,包括单核细胞、淋巴细胞、巨噬细胞和内皮细胞,在纤维蛋白溶解以及中性粒细胞和淋巴细胞的激活与趋化作用中发挥重要作用。在本研究中,我们检测了uPAR血浆浓度与肾移植功能之间的相关性。

目的

本研究纳入了78名白种人尸体供肾肾移植受者。

方法

使用市售酶联免疫吸附测定(ELISA)试剂盒测量uPAR的血浆浓度。

结果

我们观察到肾小管萎缩患者的uPAR血浆浓度升高,具有临界显著性(p = 0.095)。uPAR的血浆浓度与血清肌酐或尿素呈强统计学显著正相关,与估计肾小球滤过率(eGFR)呈强负相关。uPAR血浆浓度与尿蛋白浓度以及血液透析持续时间之间也存在临界正相关。

结论

我们的研究结果表明,肾移植受者的uPAR血浆浓度与移植肾功能显著负相关,并且在肾小管萎缩患者中可能升高。

相似文献

1
Plasma concentration of urokinase plasminogen activator receptor is a marker of kidney allograft function.尿激酶型纤溶酶原激活物受体的血浆浓度是同种异体肾移植功能的一个标志物。
Ir J Med Sci. 2018 Nov;187(4):1083-1087. doi: 10.1007/s11845-018-1767-4. Epub 2018 Mar 1.
2
Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection.急性肾移植排斥反应期间尿激酶型纤溶酶原激活剂及其受体的表达
Kidney Int. 2003 Nov;64(5):1845-53. doi: 10.1046/j.1523-1755.2003.00261.x.
3
Renal urokinase-type plasminogen activator (uPA) receptor but not uPA deficiency strongly attenuates ischemia reperfusion injury and acute kidney allograft rejection.肾组织中尿激酶型纤溶酶原激活剂(uPA)受体缺乏而非uPA缺乏,可显著减轻缺血再灌注损伤和急性肾移植排斥反应。
J Immunol. 2008 Jul 15;181(2):1179-89. doi: 10.4049/jimmunol.181.2.1179.
4
Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.急性和慢性乙型肝炎患者血浆尿激酶型纤溶酶原激活剂及尿激酶型纤溶酶原激活剂受体的评估
Thromb Res. 2009;123(3):537-42. doi: 10.1016/j.thromres.2008.06.013. Epub 2008 Aug 8.
5
[Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].[全身炎症反应综合征患者血浆中尿激酶型纤溶酶原激活剂及尿激酶型纤溶酶原激活剂受体水平的动态变化]
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2011 Aug;23(8):478-81.
6
Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China.血浆可溶性尿激酶型纤溶酶原激活物受体水平与狼疮性肾炎的临床及病理活动相关:一项来自中国的大型队列研究
Lupus. 2015 May;24(6):546-57. doi: 10.1177/0961203314558857. Epub 2014 Nov 18.
7
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.尿激酶型纤溶酶原激活物系统成分对无远处转移的透明细胞肾细胞癌患者的预后影响
BMC Cancer. 2014 Dec 18;14:974. doi: 10.1186/1471-2407-14-974.
8
Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.尿激酶型纤溶酶原激活物系统和骨桥蛋白在接受放疗的非小细胞肺癌患者中的共同检测对预后的影响及其与大体肿瘤体积的相关性。
Strahlenther Onkol. 2018 Jun;194(6):539-551. doi: 10.1007/s00066-017-1255-1. Epub 2018 Jan 16.
9
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.尿激酶型纤溶酶原激活物受体(uPAR)在血液和骨髓细胞上的结构、功能及表达
Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398.
10
Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.尿激酶型纤溶酶原激活物受体及其可溶性形式在 2 型糖尿病肾病中的表达。
Arch Med Res. 2019 Jul;50(5):249-256. doi: 10.1016/j.arcmed.2019.08.007. Epub 2019 Oct 5.

引用本文的文献

1
Innate immune modulation in transplantation: mechanisms, challenges, and opportunities.移植中的固有免疫调节:机制、挑战与机遇
Front Transplant. 2023 Dec 8;2:1277669. doi: 10.3389/frtra.2023.1277669. eCollection 2023.
2
Coagulation and Fibrinolysis in Kidney Graft Rejection.移植肾排斥反应中的凝血与纤溶。
Front Immunol. 2020 Aug 25;11:1807. doi: 10.3389/fimmu.2020.01807. eCollection 2020.

本文引用的文献

1
Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.可溶性尿激酶型纤溶酶原激活物受体和尿激酶型纤溶酶原激活物受体促成白血病中的化疗耐药性。
Oncol Lett. 2017 Jul;14(1):383-389. doi: 10.3892/ol.2017.6150. Epub 2017 May 10.
2
Soluble Urokinase Receptor and Chronic Kidney Disease.可溶性尿激酶受体与慢性肾脏病
N Engl J Med. 2016 Mar 3;374(9):890. doi: 10.1056/NEJMc1515787.
3
Soluble Urokinase Receptor and Chronic Kidney Disease.可溶性尿激酶受体与慢性肾脏病
N Engl J Med. 2015 Nov 12;373(20):1916-25. doi: 10.1056/NEJMoa1506362. Epub 2015 Nov 5.
4
Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.全长可溶性尿激酶型纤溶酶原激活物受体下调足细胞中nephrin的表达。
Sci Rep. 2015 Sep 18;5:13647. doi: 10.1038/srep13647.
5
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.采用强化血浆置换及可溶性尿激酶型纤溶酶原激活物受体介导的足细胞β3整合素激活同步监测治疗复发性原发性局灶节段性肾小球硬化症
Transplantation. 2015 Dec;99(12):2593-7. doi: 10.1097/TP.0000000000000914.
6
Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.血浆可溶性尿激酶受体水平与IgA肾病患者足细胞损伤相关。
PLoS One. 2015 Jul 13;10(7):e0132869. doi: 10.1371/journal.pone.0132869. eCollection 2015.
7
Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.尿激酶型纤溶酶原激活物受体及其可溶性形式在常见活检证实的肾脏疾病和糖尿病肾病分期中的作用
Clin Biochem. 2015 Dec;48(18):1324-9. doi: 10.1016/j.clinbiochem.2015.07.001. Epub 2015 Jul 8.
8
A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.肾小球疾病中可溶性尿激酶型纤溶酶原激活物受体的重新评估
Kidney Int. 2015 Mar;87(3):564-74. doi: 10.1038/ki.2014.346. Epub 2014 Oct 29.
9
Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.原发性局灶节段性肾小球硬化症患者的尿可溶性尿激酶受体水平升高且具有致病性。
BMC Med. 2014 May 20;12:81. doi: 10.1186/1741-7015-12-81.
10
Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor.雷帕霉素通过上调尿激酶受体促进足细胞迁移。
Transplant Proc. 2014 May;46(4):1226-8. doi: 10.1016/j.transproceed.2013.12.011.